Skip to content

The study of letrozole and GnRHa combined with growth hormone in the treatment of short pubertal boys

The study of letrozole and GnRHa combined with growth hormone in the treatment of short pubertal boys

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068405
Enrollment
Unknown
Registered
2023-02-17
Start date
2023-02-20
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

short stature

Interventions

letrozole group:letrozole+rhGH
GnRHa group:GnRHa+rhGH

Sponsors

Fuzhou Children's Hospital of Fujian
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
10 Years to 16 Years

Inclusion criteria

Inclusion criteria: Meet the diagnosis of short stature, including growth hormone deficiency, idiopathic short stature and small for gestational age children, aged between 11 and 16 years old; boys in both groups were adolescent when they were enrolled, with testes >=4ml, and gonadotropin releasing hormone (GnRH) provocation test showed that the peak value of luteinizing hormone exceeded 5 mIU/ml, and the ratio of luteinizing hormone/follicle stimulating hormone was greater than 0.6; the bone age was more than 13 years old; the pituitary MRI scan showed no abnormalities.

Exclusion criteria

Exclusion criteria: Combined with organic diseases; combined with thyroid disease, bone metabolic disorders; severe malnutrition; liver and kidney dysfunction; bone age greater than 16 years old; other conditions not suitable for the application of rhGH, GnRHa or letrozole.

Design outcomes

Primary

MeasureTime frame
height;bone age;

Secondary

MeasureTime frame
weight;BMD;metabolism;

Countries

CHINA

Contacts

Public ContactRuimin Chen

Fuzhou Children's Hospital of Fujian

chenrm321@163.com+86 591 8333 3170

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026